



Portsmouth Hospitals  
University  
NHS Trust

Clinical Delivery

# Blood Groups.


**Working together** To drive excellence in care for our patients and communities

Jennifer Mills  
17/03/2024

# Introduction

- More than just ABO/RhD!
- Initial overview:
  - Terminology
  - History
  - Clinical Significance
- Key blood groups: 3 parts.
  - Part 1: **Essential** Blood Groups
  - Part 2: **Important** Blood Groups
  - Part 3: Blood Groups that Confuse the Lab!

# Key Terminology



## Blood Groups: What?



- **Blood Group Systems** are determined by the **expression** of red cell membrane **structures**.
- **Variants** in these structures result in the different **Blood Group Antigens**.
  - Blood Group Antigens are **inherited**.
- There are **36** Blood Group Systems identified by the International Society of Blood Transfusion (ISBT).
  - There are >300 Blood Group Antigens!!
  - There are **6 Clinically Significant** Blood Group Systems.
    - These are systems are associated with **alloimmunisation** and **haemolytic reactions**.

## Blood Groups: History



- All known blood groups were discovered in the past 120 years!
  - Often discovered when a patient gave birth to a baby with Haemolytic Disease of the Foetus/New-born (HDFN).
  - Often named after the discover, or “Patient Zero!”
- **(Some) Key Discoveries:**
  - 1901: Karl Landsteiner discovers ABO
  - 1940/9141: Rh Group discovered (Landsteiner and Weiner)
  - 1946: Kell Group discovered (Coombes, Mourant and Race)
  - 1951: Kidd Group discovered (Race)

## Blood Groups: Why?



Blood Groups don't **just** exist to make transfusion difficult!

- Blood groups are cell structures, and so perform functions essential to activity and survival.
- Not all functions are understood, but include:
  - Ion transfer (Rh group)
  - Maintaining the red cell membrane (Rh, ABO)
  - Chemokine Receptor (Duffy)
  - Enzymatic Functions (Kell)


This is one of the reasons why we can't just "manufacture" safe blood!

## Why are blood groups clinically significant?



- The immune system protects the body by targeting non-self/foreign cells.
  - Foreign cells express different **antigens**.
  - Many Blood Group Antigens trigger the immune system.
  - This process is known as **alloimmunisation**.
- Repeated exposure results in a stronger response and more rapid destruction.
- Associated with clinical morbidity and mortality.

# Haemolytic Transfusion Reactions (HTR)





- HTRs occur when recipient allo-antibodies interact with the donor red cells.
- There are two types of HTR, delayed and acute.
  - Both result in destruction of transfused cells.

Feature	Acute	Delayed
Time of Onset	<24 hours.	>24 hours
Haemolysis Type	Intravascular	Extravascular
Implicated Groups	<b>ABO</b> , Duffy, Kell	All other groups e.g., Rh
Clinical Features	AKI, pain, fever, severe anxiety	Refractory anaemia, jaundice
Severity	High risk of mortality.	<b>Typically</b> , non-fatal.




# Haemolytic Transfusion Reactions (HTR)



The release of intracellular components has widespread physiological effects e.g., free radical damage.

**Intravascular Haemolysis:**  
Red cells break down in blood vessels. This is not part of the body's normal red cell processing.

**Extravascular Haemolysis:**  
Red cells break down in the liver/spleen using the body's normal systems.



While this process is “normal”, it can overwhelm the body's processing systems, especially in the comorbid.

# Haemolytic Disease of the Foetus and New-born (HDFN)



- HDFN is a significant complication of pregnancy.
  - It can result in foetal anaemia, abnormal development and pregnancy loss.




Rh-positive man



Rh-negative woman  
with Rh-positive fetus



Rh-positive fetus antigens  
can enter the mother's  
blood during delivery



Mother will produce  
anti-Rh antibodies



In the next Rh-positive  
pregnancy, mother's anti-Rh  
antibodies will attack  
fetal red blood cells


# Haemolytic Disease of the Foetus and New-born (HDFN)




- Not ALL antibodies result in HDFN.
  - The antibody must be able to cross the placenta.
- HDFN can occur because of historical transfusions!
- “High Risk” Antibodies:
  - Anti-D Prophylactic Anti-D protects patients from this.
  - Anti-c We don't have any prophylaxis for these- but they can be as severe as Anti-D.
  - Anti-K
- Management includes:
  - Monitoring antibody levels
  - Intrauterine transfusions
  - Neonatal Exchange Transfusions

# Part 1: Essential Blood Groups.

- These are the group you **MUST** understand.
  - These will cause severe, clinically significant reactions.
  - You're probably already familiar!
- This section will cover:
  - ABO (A, B, O)
  - Rh (D, C/c, E/e)
  - Kell (K, k)




# ABO




- ABO is the most well-known blood group system.
  - It's also the most important!
- ABO is a carbohydrate structure.
  - Group is determined by the “terminal carbohydrate.”
- The gene is found on chromosome 9 (9q34).
  - Patients inherit 1 allele from each parent.

		Maternal Allele		
		A	B	O
Paternal Allele	A	AA: <b>Group A</b>	AB: <b>Group AB</b>	AO: <b>Group A</b>
	B	AB: <b>Group AB</b>	BB: <b>Group B</b>	BO: <b>Group B</b>
	O	OA: <b>Group A</b>	OB: <b>Group B</b>	OO: <b>Group O</b>


# ABO: Why is it special?



Innate  
Immunity!




From 4 months of age patients  
have detectable ABO  
antibodies.




ABO antigens are **carbohydrates** so the  
immune system is exposed to them in the  
environment.



IgM antibodies can activate primary immune processes  
e.g., complement, to destroy cells intravascularly.



# ABO: Who gets what?



	Patient Group			
	A	B	AB	O
Antigen	A	B	AB	O
Antibody	Anti-B	Anti-A	None	Anti-A and Anti-B

DONOR GROUP		RECIPIENT GROUP			
		A	B	AB	O
Red Cells	A			AB is the universal Red Cell Receiver	
	B				
	AB				
	O	O is the universal red cell Donor			
Plasma	A				O is the universal Plasma Receiver
	B				
	AB	AB is the universal plasma Donor			
	O				

## ABO: Clinical Significance




- ABO Incompatible Red Cell Transfusions can be FATAL.
  - The UK Department of Health classifies it as a **never-**
- Transfusion with >50ml of blood (units are typically ~250-300ml) results in an HTR in >50% of patients, and death in 17% of cases. *(Namikawa et al. 2018)*
- haemolysis.
  - DONATION IgM attaches to the RECIPIENT red cells and destroys them intravascularly.



# Rh Group

- The Rh Blood System group contains 49 antigens!
  - D, C, c, E and e are the most important.
  - Others: f, C<sup>w</sup>, C<sup>x</sup> etc.
  - Antigens are extracellular parts of a large transmembrane protein.
- Rh-associated glycoprotein (RhAg) protein is the base.
  - Rh-null patients have no RhAg and lack all Rh antigens.
    - Golden Blood!



## Rh: Inheritance



- The Rh group is determined by multiple genes, including: ***RHD***, ***RHCE***, ***RHAG***, ***RHCG*** and ***RHBG***.
  - ***RHCE*** codes for: C, c, E, e
    - RhC/c and RhE/e are two antigens but they're coded by the same gene.
  - ***RHD*** codes for: D.
    - There is NO antithetical for D.
    - Others genes are associated with the base protein.
- ***RHCE*** and ***RHD*** are inherited together (haplotype).
  - To keep track, labs use nomenclature.

# Rh: Inheritance



Weiner	Fisher-Race	Antigens
R0	Dce	D, c, e
R1	DCe	D, C, e
R2	DcE	D, c, E
RZ	DCE	D, C, E
r	dce	c, e
r'	dCe	C, e
r''	dcE	c, E
ry	dCE	C, E

Historically, population frequencies, could be used to predict the risk of a foetus being incompatible with the pregnant person. **Now we use genetic analysis.**

Example: Parent Phenotypes		Maternal: D- C+ c+ E- e+	
		r dce	r' dCe
Paternal: D+ C- c+ E+ e+	R2 DcE	DcE/dce	DcE/dCe
	r dce	dce/dce	dce/dCe

These foetuses would be RhD+

These foetuses would be RhD-

The other option is R0 (Dce), but this is uncommon in Caucasians.


# RhD

- RhD is the second most important antigen after A and B
  - It's highly antigenic.
    - Because it's a **unique protein**.
  - **Exposure = alloimmunisation**
- RhD varies across populations
  - Caucasian population 85% Rh D Positive.
  - Asians/Native American 99% Rh D Positive.
  - Important when considering HDFN risks.

## Rh Antibodies

- Rh Antibodies occur **only** after exposure to cells expressing antigens the recipient is lacking.
  - No innate antibodies here!
  - Rh is a protein so antibodies are IgG and can cross
- Patients of childbearing age and those requiring chronic transfusions should be matched for their Rh group where possible to reduce later complications.
- variable antigenicity.
  - **Most antigenic**  $c > E > C > e$  **Least Antigenic**
- Antibodies to the Rh antigens can result in delayed HTRs.
- The main Rh antigens are all implicated in HDFN.

# Kell System




- 39 antigens.
- Only a couple are clinically significant.
  - **K/k**
  - Kpa/Kpb
  - Jsa/Jsb

	<b>K/k</b>	<b>Kp<sup>a</sup> / Kp<sup>b</sup></b>	<b>Js<sup>a</sup> / Js<sup>b</sup></b>
Phenotypes	<b>K-k+</b> <ul style="list-style-type: none"> <li>• 91% Caucasians</li> <li>• 98% Black</li> </ul>	<b>Kp (a-b+)</b> <ul style="list-style-type: none"> <li>• 97.7% Caucasians</li> <li>• 100% Black</li> </ul>	<b>Js (a-b+)</b> <ul style="list-style-type: none"> <li>• 100% Caucasians</li> <li>• 80% Black</li> </ul>
	<b>K+k-</b> <ul style="list-style-type: none"> <li>• 0.2% Caucasians</li> <li>• Rare in Blacks</li> </ul>		<b>Js (a+ b-)</b> <ul style="list-style-type: none"> <li>• &lt;1% Caucasians</li> <li>• 20% Blacks</li> </ul>
	<b>K+k+</b> <ul style="list-style-type: none"> <li>• 8.8% Caucasians</li> <li>• 2% Blacks</li> </ul>		

## Kell: Clinical Significance.

- Anti-K
  - **IgG antibody:** Delayed HTRs.
  - Anti-K is associated with **severe** HDFN.
    - Anti-K can suppress the production of foetal red cells.
    - Destroys erythroblasts in the foetal liver.
    - **There is no current prophylaxis.**
- Anti-k very rare!
  - But very hard to manage – as >99% of humans are k+.
- Other antibodies can cause delayed HTRs and mild HDFN.

# Part 1: How can we protect patients?




	Blood Group System			
	ABO	RhD	RhCE	Kell
Sampling	2 separate samples are required for fully matched units (WBIT protection)		N/A	
Testing	ABO/RhD results must agree across both samples. All anomalies resolved.		High risk patients are phenotyped for Rh/K.	
Component Selection	ABO compatible or HT- plasma products.	RhD matched.	Blood selected for high-risk patients should match their phenotype.	
Emergency Situations.	Group O <b>ONLY</b> .	<b>ONEG</b> if childbearing potential. <b>OPOS</b> if not.	<b>OPOS:</b> C+/c- E-/e+ <b>ONEG:</b> C-/c+ E-/e+	K-

Emergency Units aren't always safe- If in doubt, ask the Lab!





## Part 2: Important Blood Groups.

- These blood groups:
  - Often result in antibodies.
  - Can be clinically significant.
- This section includes:
  - Duffy
  - Kidd
  - Lutheran
  - MNS




# Duffy and MNS




	Duffy	MNS
Antigens	<ul style="list-style-type: none"> <li>• 6 Antigens Known</li> <li>• Fya and Fyb are the most important.</li> <li>• Codominant Expression</li> </ul>	<ul style="list-style-type: none"> <li>• 50 glycoprotein antigens!</li> <li>• M, N, S, s, are the most important. <ul style="list-style-type: none"> <li>• M/N are antithetical</li> <li>• S/s are antithetical.</li> </ul> </li> </ul>
Antibodies	IgG	IgM and IgG
Significance	<ul style="list-style-type: none"> <li>• Moderately severe delayed HTRs.</li> <li>• Mild HDFN.</li> <li>• Black patients are at high risk of antibody development as many are Fya and Fyb negative.</li> </ul>	<ul style="list-style-type: none"> <li>• Anti-M and N are often cold IgM, and not significant.</li> <li>• Anti-M and N can cause HDFN, but it's very rare!</li> <li>• Anti-S and s are IgG and cause HDFN and HTRs.</li> </ul>

# Kidd and Lutheran



	Kidd	Lutheran
Antigens	<ul style="list-style-type: none"> <li>• 3 antigens.</li> <li>• Jka, Jkb and Jk3</li> <li>• Jka/Jkb are codominant</li> </ul>	<ul style="list-style-type: none"> <li>• 19 antigens with 4 pairs of antithetical antigens.</li> <li>• Lu(a)/Lu(b) are the pair of interest and are codominant.</li> </ul>
Antibodies	IgG	IgG
Significance	<ul style="list-style-type: none"> <li>• Severe and fatal delayed HTRs.</li> <li>• Antibodies can fall to low or undetectable levels.</li> <li>• Typically, mild HDFN.</li> </ul>	<ul style="list-style-type: none"> <li>• Mild HTRs.</li> <li>• Mild HDFN treated with phototherapy.</li> </ul>


## Part 2: How do we protect patients?




- If a patient is identified with a significant antibody, they **MUST** receive antigen negative units.
  - Even if the antibody is no longer detected.
  - Exceptions are made in emergencies.
- Patients with antibodies are at risk of developing more.
  - Future transfusions are Rh/K phenotyped where possible.
  - More antibodies = Harder to Match for!
- Pregnant patients need close monitoring.
  - Antibody titre monitoring.
  - Antenatal testing e.g., Middle Cerebral Artery Doppler.

## Part 3: The Groups that Confuse the Lab!


- There are 300 blood group antigens!
  - Not all are clinically significant or result in antibodies .
- But they can complicate transfusions.
  - They can be non-specific or pan-reactive.
- The Lab may not know what the antibody is.
- The Lab may not be able to crossmatch in house!




## High Frequency Antigens

- Antigens which appear on 99% of the population.
  - Your patient is the 1%!
- Antigens include: 99% 
  - Vel
  - k
  - Yt<sup>a</sup>
  - Ch<sup>a</sup>
  - Rg<sup>a</sup>
- Antibodies are often described as “pan-reactive.”
- Clinical significance varies.
  - Some can cause mild HDFN (k and Vel) and mild HTRs.
  - Most will make crossmatching difficult.

## Low Frequency Antigens

- Antigens which appear on only 1% of the population.
  - Your patient was (unluckily) transfused with a unit from one of these donors.
- Antigens include 1% 
  - C<sup>w</sup>
  - W<sup>r</sup><sup>a</sup>
  - K<sup>p</sup><sup>a</sup>
  - J<sup>s</sup><sup>a</sup>
- Antibodies are often described as “non-specific.”
- Antibodies typically aren’t clinically significant.
  - Low frequency Rh e.g., C<sup>w</sup> have been associated with significant HDFN.

## Part 3: How do we protect patients?




- Depends on the pattern of reactions.
- Any antibody positive patients are manually crossmatched.
  - Units will NOT be issued if patient plasma reacts with cells.
    - Exceptions made in emergencies.
- **Non-specific Reactions (low frequency antigens)**
  - Empirical crossmatch (selecting “best match” units)
- **Pan-reactive Reactions (high frequency antigens)**
  - Send to referral laboratory.
    - This will delay access of “safe” blood for at least 12 hours, usually 24-hour TAT.



The End!

Thank you for listening.

Any Questions?



**Working together** To drive excellence in care for  
our patients and communities

---